Neurizon Therapeutics (ASX:NUZ) appointed Kathryn Williams as chief regulatory officer, Jeffrey Brown as chief scientific adviser, and Chris Freitag as chief medical adviser, according to a Thursday Australian bourse filing.
Williams has 20 years of experience in regulatory affairs, securing fast track and orphan designations with regulatory bodies, the filing said.
Brown also has over 20 years of experience in drug development experience in neurology programs.
Freitag is a medical doctor with nearly 30 years of medical and pharmaceutical experience focusing on oncology and rare diseases.
The company's shares rose 15% in recent Thursday trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。